EP1924258A1 — IMPROVED PHARMACEUTICAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF
Assigned to Pharmathen SA · Expires 2008-05-28 · 18y expired
What this patent protects
The present invention relates to the formulation of solid dosage forms comprising a therapeutically effective amount of an HMG-CoA reductase inhibitor, and especially Fluvastatin or Atorvastatin or salts thereof, in combination with inorganic silica polymer such as Dimethicone, a…
USPTO Abstract
The present invention relates to the formulation of solid dosage forms comprising a therapeutically effective amount of an HMG-CoA reductase inhibitor, and especially Fluvastatin or Atorvastatin or salts thereof, in combination with inorganic silica polymer such as Dimethicone, and a process for the preparation thereof by direct compression.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.